An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM.
O'Farrell AM, et al.
Clin Cancer Res. 2003 Nov 15;9(15):5465-76.
Clin Cancer Res. 2003.
PMID: 14654525
Clinical Trial.